Opportunity

The gut microbiome has been implicated in a number of chronic diseases. Bacterial therapies offer promise to restore the healthy composition of the gut and treat disease, but many of these therapies do not effectively populate the gut.

Solution

Ancilia are developing a new class of engineered bacterial therapies that effectively alter the human to treat the growing number of diseases linked to the microbiome.